Drug Profile
Research programme: myogenic stem cell therapy - Andain
Alternative Names: OrCell Myogenic cells; OrCell stem cell therapyLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Andain
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemia; Musculoskeletal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia in Israel (Parenteral, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in Israel (Parenteral, Injection)
- 07 Sep 2011 Preclinical trials in Ischaemia in Israel (Parenteral, Injection)